Nautilus Biotechnology (NAUT) Expected to Announce Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is expected to post its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect Nautilus Biotechnology to post earnings of ($0.1450) per share and revenue of $0.25 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Nautilus Biotechnology Stock Performance

Shares of NASDAQ NAUT opened at $2.96 on Tuesday. The company’s fifty day moving average price is $2.86 and its 200 day moving average price is $2.16. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $4.31. The company has a market capitalization of $374.62 million, a PE ratio of -6.30 and a beta of 1.08.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NAUT. Guggenheim increased their price objective on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and an average target price of $4.00.

Insider Transactions at Nautilus Biotechnology

In other news, CEO Sujal M. Patel acquired 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was purchased at an average cost of $2.61 per share, for a total transaction of $65,250.00. Following the completion of the transaction, the chief executive officer owned 10,366,721 shares in the company, valued at approximately $27,057,141.81. This trade represents a 0.24% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 41.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in Nautilus Biotechnology during the fourth quarter worth about $228,000. Jane Street Group LLC boosted its stake in Nautilus Biotechnology by 304.1% during the second quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after buying an additional 218,512 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Nautilus Biotechnology during the fourth quarter worth about $204,000. Jacobs Levy Equity Management Inc. purchased a new position in Nautilus Biotechnology during the first quarter worth about $194,000. Finally, Squarepoint Ops LLC boosted its stake in Nautilus Biotechnology by 29.5% during the third quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after buying an additional 30,005 shares during the period. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.